| 3.2 0.41 (14.7%) | 08-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.33 |
1-year : | 5.06 |
| Resists | First : | 3.71 |
Second : | 4.33 |
| Pivot price | 2.6 |
|||
| Supports | First : | 2.66 |
Second : | 2.02 |
| MAs | MA(5) : | 2.94 |
MA(20) : | 2.68 |
| MA(100) : | 5.27  |
MA(250) : | 9.45 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 56.8 |
D(3) : | 53.4 |
| RSI | RSI(14): 55.6 |
|||
| 52-week | High : | 22.2 | Low : | 2.02 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ FEMY ] has closed below upper band by 4.6%. Bollinger Bands are 41.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.35 - 3.37 | 3.37 - 3.38 |
| Low: | 2.73 - 2.74 | 2.74 - 2.76 |
| Close: | 3.17 - 3.2 | 3.2 - 3.23 |
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.
Thu, 27 Aug 2026
Femasys Market Sentiment - Benzinga España
Wed, 26 Aug 2026
For the first time, UNC Health OB/GYNs can offer Femasys fertility care - Stock Titan
Thu, 20 Aug 2026
Biotech Femasys (NASDAQ: FEMY) raises $30M in private round - Stock Titan
Wed, 19 Aug 2026
Femasys Inc. Announces FDA Approval of Modular PMA Pathway for FemBloc in the U.S. - Quiver Quantitative
Fri, 14 Aug 2026
Femasys Inc. (NASDAQ: FEMY) narrows first-half loss, completes $30M financing - Stock Titan
Fri, 14 Aug 2026
Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 0 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 2.48e+006 (%) |
| Held by Institutions | 3.8 (%) |
| Shares Short | 190 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.723e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 526.6 % |
| Return on Equity (ttm) | -84.3 % |
| Qtrly Rev. Growth | 2.3e+006 % |
| Gross Profit (p.s.) | 0.48 |
| Sales Per Share | 0.78 |
| EBITDA (p.s.) | -5.31 |
| Qtrly Earnings Growth | -2.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 4.06 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 264930 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|